Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT 1 receptor subtype

Journal of Pineal Research

Volumn 35, Issue 3, 2003, Pages 177-182

  Shiu, Stephen Y W ^a,d   Law, In C ^b   Lau, Kai W ^a   Tam, Po C ^a   Yip, Andrew W C ^b   Ng, Wai T ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c YAN CHAI HOSPITAL   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

2 125I iodomelatonin; Pineal; Platelet; Prostate specific antigen

Indexed keywords

2 IODOMELATONIN; 4 PHENYL 2 PROPIONAMIDOTETRALINE; 6 HYDROXYMELATONIN; IODINE 125; LIGAND; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN RECEPTOR; N ACETYLSEROTONIN; PROSTATE SPECIFIC ANTIGEN; RECEPTOR SUBTYPE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; BINDING COMPETITION; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER TISSUE; CASE REPORT; CELL LINE; CLINICAL TRIAL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATIENT; PLACENTA; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; SAMPLE; TRANSURETHRAL RESECTION; TROPHOBLAST;

AGED; CELL DIVISION; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MALE; MELATONIN; PROSTATIC NEOPLASMS; RECEPTOR, MELATONIN, MT1;

EID: 0042412174     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00074.x     Document Type: Article

References (23)

1. PANZER A, VILJOEN M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997; 22:184-202.
2. BRZEZINSKI A. Melatonin in humans. N Engl J Med 1997; 336:186-195.
3. REPPERT SM, WEAVER DR, EBISAWA T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13:1177-1185.
4. 1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92:8734-8738.
5. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
6. 1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 2000; 29:172-183.
7. 1 receptor protein expression. Prostate 2001; 46:52-61.
8. SIU SWF, LAU KW, TAM PC et al. Melatonin and prostate cancer cell proliferation: Interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52:106-122. (Erratum, Prostate 2002; 52: 252.)
9. LUPOWITZ Z, ZISAPEL N. Hormonal interactions in human prostate tumor LNCaP cells. J Steroid Biochem Mol Biol 1999; 68:83-88.
10. MORETTI RM, MARELLI MM, MAGGI R et al. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 2000; 7:347-351.
11. GUARDIOLA-LEMAITRE B. Toxicology of melatonin. J Biol Rhythms 1997; 12:697-706.
12. SEABRA MLV, BIGNOTTO M, PINTO LR et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29:193-200.
13. 125I]Iodomelatonin binding sites in the human kidney and the effect of guanosine 5′ -O-(3-thiotriphosphate). J Clin Endocrinol Metab 1995; 80:1560-1565.
14. 1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997; 11:93-100.
15. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-3108.
16. SHIU SYW, XI SC, XU JN et al. Inhibition of malignant trophoblastic cell proliferation in vitro and in vivo by melatonin. Life Sci 2000; 67:2059-2074.
17. PATEL A, DOREY F, FRANKLIN Jet al. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-1445.
18. SCHMID H-P, SEMJONOW A, MAIBACH R. Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer. J Clin Oncol 1999; 17:1645-1646.
19. LAUDON M, GILAD E, MATZKIN H et al. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab 1996; 81:1336-1342.
20. GILAD E, LAUDON M, MATZKIN H et al. Functional melatonin receptors in human prostate epithelial cells. Endocrinology 1996; 137:1412-1417.
21. SCHMID H-P, MAIBACH R, BERNHARD J et al. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer 1997; 79:1703-1709.
22. LISSONI P, CAZZANIGA M, TANCINI G et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol 1997; 31:178-181.
23. LISSONI, P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10:110-116.